Life sciences company Avantor (NYSE: AVTR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $1.69 billion. Its non-GAAP profit of $0.21 per share was 11% above analysts’ consensus estimates.
Is now the time to buy AVTR? Find out in our full research report (it’s free for active Edge members).
Avantor (AVTR) Q2 CY2026 Highlights:
- Revenue: $1.69 billion vs analyst estimates of $1.61 billion (flat year on year, 4.9% beat)
- Adjusted EPS: $0.21 vs analyst estimates of $0.19 (11% beat)
- Adjusted EBITDA: $254.3 million vs analyst estimates of $235.2 million (15% margin, 8.1% beat)
- Adjusted EPS guidance for the full year is $0.82 at the midpoint, beating analyst estimates by 3.3%
- Operating Margin: 7.2%, in line with the same quarter last year
- Organic Revenue was flat year on year (beat)
- Market Capitalization: $9.73 billion
StockStory’s Take
Avantor’s second quarter was marked by a positive market response, as results surpassed Wall Street expectations for both revenue and non-GAAP earnings. Management attributed the performance to accelerated progress in its Revival transformation program, particularly within the VWR distribution and services segment, which returned to organic growth. CEO Emmanuel Ligner emphasized the impact of deliberate commercial and operational changes, including digital upgrades and customer segmentation. The Bioscience & Medtech Products segment also showed sequential improvement, with strong order intake and operational enhancements. These factors combined to support a stable operating margin and robust free cash flow generation, allowing for continued investment and debt reduction.
Looking ahead, Avantor’s raised full-year guidance is built on expectations for accelerating growth in VWR and a return to organic growth for Bioscience & Medtech Products. Management highlighted ongoing investments in digital platforms, supply chain, and talent as foundational for sustainable improvement. CFO Steve Eck noted that targeted cost discipline and operational efficiencies are intended to offset inflationary pressures, while the order pipeline and improved customer mix position the company for margin stability. Ligner stated, “We will exit the year with momentum,” underscoring confidence in the Revival program’s ability to drive durable growth into 2027.
Key Insights from Management’s Remarks
Management cited deliberate commercial and operational changes as the primary drivers behind the quarter’s performance, with digital transformation, customer segmentation, and execution on Revival initiatives contributing to outperformance.
- VWR Segment Momentum: The VWR distribution and services segment returned to organic growth, with management crediting targeted actions such as relaunching vwr.com, investing in e-commerce capabilities, and strengthening relationships with large global customers. These steps resulted in increased market share and higher engagement, particularly among small and midsized customers.
- Digital Transformation Progress: Upgrades to the digital platform, including the VWR.com relaunch, drove higher conversion rates and direct traffic. Management noted that digital enhancements are in early stages but already contributing meaningfully to growth, especially in Europe and among higher-margin customer segments.
- Operational Improvements in BMP: The Bioscience & Medtech Products segment saw sequential revenue growth, supported by double-digit order intake and a book-to-bill ratio above 1. Management attributed this to focused commercial efforts, supply chain investments, and improved execution within process chemicals and fluid handling subsegments.
- Cost Discipline and Organizational Simplification: Avantor continued to reduce headcount and streamline processes, including a redesigned customer onboarding procedure that halved completion time. These actions supported margin stability and allowed for reinvestment in growth.
- Revival Program Impact: The company’s Revival program, launched to sharpen strategic focus and improve execution, has refreshed a quarter of senior leadership and introduced lean manufacturing, Six Sigma tools, and cross-functional collaboration. Management views Revival as an evolving initiative underpinning both current results and future potential.
Drivers of Future Performance
Avantor’s outlook for the remainder of the year is anchored by momentum in its core segments, ongoing digital investments, and continued operational efficiencies to balance inflationary pressures.
- Accelerating VWR Growth: Management expects the VWR segment’s growth to strengthen in the second half, driven by improved commercial execution, a more favorable customer mix, and continued gains from digital engagement. Ligner noted that reduced headwinds from earlier contract renewals should further support growth.
- BMP Recovery and Order Book Strength: The Bioscience & Medtech Products segment is projected to return to growth, supported by a robust order book and easing comparisons from discrete headwinds in prior periods. Subsegments such as process chemicals and advanced tech are expected to benefit from healthy end markets and operational improvements.
- Margin Stability Amid Cost Pressures: Despite ongoing inflationary headwinds, management plans to maintain stable adjusted EBITDA margins through cost discipline, productivity enhancements, and investments in higher-margin digital channels. CFO Steve Eck highlighted digital sales to small customers and targeted headcount reductions as key levers to offset external pressures.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will watch (1) whether VWR’s digital and commercial initiatives continue to deliver above-market growth, (2) the pace of recovery and order conversion in Bioscience & Medtech Products, and (3) execution on cost discipline and organizational streamlining to support margin stability. Updates on the Revival program and progress at the December Investor Day will also be important indicators.
Avantor currently trades at $14.27, up from $12.42 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
